AMONGAgreement and Plan of Merger • April 24th, 2001 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledApril 24th, 2001 Company Industry Jurisdiction
Exhibit 2.2 FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT This FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (this "Amendment") is dated as of March 17, 2004 (the "Effective Date"), by and between ANTIGENICS INC., a Massachusetts corporation and a...Asset Purchase Agreement • April 1st, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledApril 1st, 2004 Company Industry Jurisdiction
WITNESSETHLicense Agreement • February 3rd, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Florida
Contract Type FiledFebruary 3rd, 2000 Company Industry Jurisdiction
1 EXHIBIT 10.4 ANTIGENICS INC. INDEMNIFICATION AGREEMENT ------------------------- This Agreement dated ______________________ is between Antigenics Inc. (the "Company"), a Delaware corporation, and ______________________ (the "Indemnitee"), who is...Indemnification Agreement • November 30th, 1999 • Antigenics Inc /De/ • Delaware
Contract Type FiledNovember 30th, 1999 Company Jurisdiction
EXHIBIT 4.2 ANTIGENICS INC. REGISTRATION RIGHTS AGREEMENT January 25, 2005 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made and entered into as of January 25, 2005, by and among Antigenics Inc., a Delaware...Registration Rights Agreement • January 25th, 2005 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
Contract Type FiledJanuary 25th, 2005 Company Industry Jurisdiction
INDENTUREAntigenics Inc /De/ • November 27th, 2001 • Biological products, (no disgnostic substances) • Massachusetts
Company FiledNovember 27th, 2001 Industry Jurisdiction
MiNK Therapeutics, Inc. (a Delaware corporation) 3,333,334 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 28th, 2021 • Agenus Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 28th, 2021 Company Industry Jurisdiction
Common Stock ($0.01 Par Value)Underwriting Agreement • January 27th, 2003 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
Contract Type FiledJanuary 27th, 2003 Company Industry Jurisdiction
RecitalsLease • May 7th, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
Contract Type FiledMay 7th, 2004 Company Industry
RECITALSSublease Agreement • August 13th, 2002 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledAugust 13th, 2002 Company Industry Jurisdiction
LICENSE AGREEMENT -----------------License Agreement • November 30th, 1999 • Antigenics Inc /De/ • New York
Contract Type FiledNovember 30th, 1999 Company Jurisdiction
Exhibit 10.1 This Agreement is dated June 21, 2004 and is made between Antigenics Therapeutics Limited having its registered offices at 25/28 North Wall Quay, Dublin 1 Registered No. 381308 ("The Company") and Peter Thornton of Dublin, Ireland ("Chief...Agreement • August 9th, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledAugust 9th, 2004 Company Industry Jurisdiction
SECURITIES PURCHASE AGREEMENT (as amended to date)Securities Purchase Agreement • September 19th, 2013 • Agenus Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 19th, 2013 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of September 18, 2013, between Agenus Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AMENDMENT AGREEMENT The Letter Agreement of June 3, 1998 between Antigenics L.L.C. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. is hereby amended as follows: -ON PAGE 1, THE INITIAL SIX LINES: "Gentlemen: We refer to our recent discussions...Amendment Agreement • January 10th, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
Contract Type FiledJanuary 10th, 2000 Company Industry
EXHIBIT 99.1 AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • August 24th, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 24th, 2000 Company Industry Jurisdiction
Exhibit 4.3 [Face of Security] ANTIGENICS INC. Certificate No. _______ [INSERT PRIVATE PLACEMENT LEGEND AND GLOBAL SECURITY LEGEND] 5.25% Convertible Senior Note due 2025 CUSIP No. ____________ Antigenics Inc., a Delaware corporation (the "COMPANY"),...Antigenics Inc /De/ • May 24th, 2005 • Biological products, (no disgnostic substances)
Company FiledMay 24th, 2005 Industry
RECITALSLicense Agreement • August 27th, 2003 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Connecticut
Contract Type FiledAugust 27th, 2003 Company Industry Jurisdiction
AGENUS INC. Common Stock (par value $0.01 per share) At Market Issuance Sales AgreementAgenus Inc • July 22nd, 2020 • Biological products, (no disgnostic substances) • New York
Company FiledJuly 22nd, 2020 Industry Jurisdiction
AGENUS INC. Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • October 18th, 2017 • Agenus Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 18th, 2017 Company Industry JurisdictionAgenus Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
FORM OF WARRANT] NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK FOR WHICH IT IS EXERCISABLE HAVE BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY APPLICABLE STATE OR FOREIGN SECURITIES LAWS...Antigenics Inc /De/ • January 24th, 2000 • Biological products, (no disgnostic substances) • Delaware
Company FiledJanuary 24th, 2000 Industry Jurisdiction
Common Stock ($0.01 Par Value)Underwriting Agreement • January 11th, 2002 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
Contract Type FiledJanuary 11th, 2002 Company Industry Jurisdiction
FLEXIBLE STANDARDIZED 401(k) PROFIT SHARING PLAN ADOPTION AGREEMENT =========== ===================================================================== --------- ----------------------------------------------------------------------- SECTION 1. EMPLOYER...Antigenics Inc /De/ • January 10th, 2000 • Biological products, (no disgnostic substances)
Company FiledJanuary 10th, 2000 Industry
RECITALS:Patent License Agreement • February 3rd, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 3rd, 2000 Company Industry Jurisdiction
IT IS AGREED:Research Agreement • March 31st, 2005 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Connecticut
Contract Type FiledMarch 31st, 2005 Company Industry Jurisdiction
RECITALSStockholder Voting Agreement • April 24th, 2001 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledApril 24th, 2001 Company Industry Jurisdiction
ANDAsset Purchase Agreement • April 1st, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledApril 1st, 2004 Company Industry Jurisdiction
EXHIBIT 10.7 MASTER LOAN AND SECURITY AGREEMENT Master Loan and Security Agreement No. S7020, dated November 19, 1998 FINOVA TECHNOLOGY FINANCE, INC. ("we," "us" or "FINOVA") is willing to make a loan (the "Loan") to ANTIGENICS, LLC ("you" or...Master Loan and Security Agreement • November 30th, 1999 • Antigenics Inc /De/ • Arizona
Contract Type FiledNovember 30th, 1999 Company Jurisdiction
RECITALSLicense Agreement • May 15th, 2003 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Connecticut
Contract Type FiledMay 15th, 2003 Company Industry Jurisdiction
EXHIBIT 10.5 CUMMINGS PROPERTIES MANAGEMENT, INC. STANDARD FORM COMMERCIAL LEASE In consideration of the covenants herein contained, Cummings Properties Management, Inc., hereinafter called LESSOR, does hereby lease to ANTIGENICS, L.L.C. (A DE...1 • November 30th, 1999 • Antigenics Inc /De/ • New York
Contract Type FiledNovember 30th, 1999 Company Jurisdiction
EXHIBIT 4.3 ANTIGENICS L.L.C. SUBSCRIPTION AGREEMENT Antigenics L.L.C. 630 Fifth Avenue Suite 2170 New York, New York 10111 Ladies and Gentlemen: 1. SUBSCRIPTION FOR UNITS. The undersigned, intending to be legally bound, hereby irrevocably applies to...Subscription Agreement • January 24th, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
Contract Type FiledJanuary 24th, 2000 Company Industry Jurisdiction
WITNESSETH:Employment Agreement • November 30th, 1999 • Antigenics Inc /De/ • New York
Contract Type FiledNovember 30th, 1999 Company Jurisdiction
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 10th, 2013 • Agenus Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 10th, 2013 Company Industry JurisdictionTHIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 15, 2013 (the “Effective Date”) among (a) SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and (b) AGENUS INC., a Delaware corporation (“Agenus”) and ANTIGENICS INC., a Massachusetts corporation (“Antigenics”) (Agenus and Antigenics are individually and collectively, jointly and severally, “Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
July 30, 2004Antigenics Inc /De/ • August 12th, 2004 • Biological products, (no disgnostic substances) • New York
Company FiledAugust 12th, 2004 Industry Jurisdiction
RECITALSRight of First Refusal Agreement • May 27th, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMay 27th, 2004 Company Industry Jurisdiction
AGENUS INC. 19,335,653 Shares of Common Stock1 UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2014 • Agenus Inc • Biological products, (no disgnostic substances) • Illinois
Contract Type FiledFebruary 6th, 2014 Company Industry Jurisdiction